Pharmacology/Pharmaceutical Industry
Acute pain management pearls: a focused review for the hospital clinician
17 Feb, 2023 | 12:42h | UTCAcute Pain Management Pearls: A Focused Review for the Hospital Clinician – Healthcare
M-A | Association between antimicrobial stewardship programs and antibiotic use globally
16 Feb, 2023 | 15:21h | UTCCommentaries:
Antimicrobial Stewardship Programs Beneficial for Cutting Antibiotic Use – HealthDay
M-A | Worldwide prevalence of antibiotic-associated Stevens-Johnson syndrome and toxic epidermal necrolysis
16 Feb, 2023 | 15:04h | UTCSummary: The article examined the prevalence Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) associated with antibiotics worldwide. The analysis included 38 studies involving 2,917 patients, which showed that 28% of SJS/TEN cases were associated with antibiotics. Among antibiotic-associated SJS/TEN, the sulfonamide class was associated with 32% of cases, followed by penicillins, cephalosporins, fluoroquinolones, and macrolides.
Article: Worldwide Prevalence of Antibiotic-Associated Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review and Meta-analysis – JAMA Dermatology (free for a limited period)
*Note: This summary was created through the collaboration of a medical editor and ChatGPT.
Guideline Synopsis | The use of opioids in the management of chronic pain
15 Feb, 2023 | 16:16h | UTCSummary: The VA/DoD guideline for chronic pain management recommends non-opioid treatments, such as cognitive-behavioral and physical therapy, with opioid use reserved for specific circumstances. Mental health evaluations are emphasized, along with regular treatment reassessments. Opioid use is not recommended due to small benefits outweighed by risks, but if used, buprenorphine is suggested due to a lower risk profile. Screening for mood disorders and traumatic brain injury is also advised, although evidence for risk mitigation strategies is lacking.*
Commentary: Initiation of Opioids Not Recommended for Chronic Pain – HealthDay
*Note: This summary was created through the collaboration of a medical editor and ChatGPT.
Cohort Study | In utero exposure to ADHD medication does not seem to result in worse offspring neurodevelopmental outcomes
14 Feb, 2023 | 10:54h | UTCSummary: The authors conducted a study to investigate the long-term effects of in utero exposure to ADHD medication (methylphenidate, amphetamine, dexamphetamine, lisdexamphetamine, modafinil, atomoxetine, clonidine) on offspring. The study followed 1,068,073 liveborn singletons from 1998 to 2018 and compared the outcomes of children whose mothers continued or discontinued ADHD medication during pregnancy. The main outcomes were neurodevelopmental psychiatric disorders, impairments in vision or hearing, epilepsy, seizures, or growth impairment during childhood or adolescence. After adjustment for demographic and psychiatric characteristics of the mother, no increased risk of any developmental disorders was found in offspring exposed to ADHD medication compared to those not exposed. The results provide reassurance for women with ADHD who depend on medication and consider continuing it during pregnancy.
(By ChatGPT, reviewed and edited)
Article: In utero exposure to ADHD medication and long-term offspring outcomes – Molecular Psychiatry (link to abstract – $ for full-text)
Commentary from the author on Twitter (thread – click for more)
In-utero exposure to ADHD medication is not associated with long-term adverse neurodevelopmental disorders and growth restriction in the offspring.
Read the thread below ?on our new paper just published in @molpsychiatry
? https://t.co/MKZ0aeFnhU#ADHD— Kathrine Bang Madsen (@Kathrine_BaMa) February 9, 2023
Recommended adult immunization schedule, United States, 2023
13 Feb, 2023 | 13:06h | UTCRecommended Adult Immunization Schedule, United States, 2023 – Annals of Internal Medicine
Commentary: Recommended 2023 Adult Immunization Schedule Published – HealthDay
Commentary on Twitter
The 2023 #ACIP schedule is out now with important changes to #COVID19 and pneumococcal vaccines, including recommendations for adults who have previously received PCV13 and PPSV23: https://t.co/QeErLZJFuZ pic.twitter.com/BR6aa1kNKi
— Annals of Int Med (@AnnalsofIM) February 10, 2023
Updated child and adolescent immunization schedule, United States, 2023
13 Feb, 2023 | 13:05h | UTCChild and Adolescent Immunization Schedule by Age – Centers for Diseases Control and Prevention
See also: Recommended Childhood and Adolescent Immunization Schedule: United States, 2023 – Pediatrics
Commentary: Immunization Schedule for Children, Teens Updated for 2023 – HealthDay
RCT | A deprescribing intervention reduced medication burden among older adults in post-acute care
13 Feb, 2023 | 12:50h | UTCDeprescribing Medications Among Older Adults From End of Hospitalization Through Postacute Care: A Shed-MEDS Randomized Clinical Trial – JAMA Internal Medicine (free for a limited period)
Related:
Deprescribing proton pump inhibitors – Australian Journal of General Practice
Antihypertensive Deprescribing in Older Adults: a Practical Guide – Current Hypertension Reports
Deprescribing in Palliative Cancer Care – Life
Less is More: Deprescribing Medications in Older Adults with Kidney Disease: A Review – Kidney360
Polypharmacy Management in Older Patients – Mayo Clinic Proceedings
Eliminating Medication Overload: A National Action Plan – Lown Institute
Common ED Medication Errors: Polypharmacy – emDocs
Current and future perspectives on the management of polypharmacy – BMC Family Practice
Polypharmacy—an Upward Trend with Unpredictable Effects – Deutsches Ärzteblatt international
Clinical Consequences of Polypharmacy in Elderly – Expert Opinion on Drug Safety
Commentary on Twitter
A randomized trial of patient-centered #deprescribing in the acute care setting reduced medication burden by 14% among older hospitalized patients that needed ongoing post-acute care. https://t.co/FJf53O00Cv #ShedMEDS #polypharmacy #LessIsMore #Geriatrics
— JAMA Internal Medicine (@JAMAInternalMed) February 9, 2023
M-A | Prevalence of polypharmacy and potentially inappropriate medication use in older lung cancer patients
9 Feb, 2023 | 13:24h | UTC
Evaluation of a 12-gene pharmacogenetic panel to prevent adverse drug reactions
7 Feb, 2023 | 14:13h | UTCA 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study – The Lancet (link to abstract – $ for full-text)
News Releases:
Matching medication to DNA leads to 30% fewer side effects – University of Liverpool
Genetic analysis can reduce adverse drug reactions by 30 per cent – Karolinska Institutet
Commentary from one of the authors on Twitter
A journey which started in 2016 has led to the publication of the #PREPARE study in @TheLancet today. In this #randomised study, we show that a 12-gene panel can reduce #adverse_effects by 30%. https://t.co/vj7gYzgxyf @CDSS_Liverpool @pandtuol pic.twitter.com/tjgFWDuTQf
— Munir Pirmohamed (@MPUoL) February 3, 2023
Cohort Study | The use of 5-alfa-reductase inhibitors may increase the risk of depression, but not dementia
7 Feb, 2023 | 13:35h | UTCAssociation of 5α-Reductase Inhibitors With Dementia, Depression, and Suicide – JAMA Network Open
Commentary: 5α-Reductase Inhibitors Linked to Depression, but Not Dementia – HealthDay
Efficacy, safety, and tolerability of antidepressants for pain in adults: overview of systematic reviews
2 Feb, 2023 | 15:05h | UTCEditorial: Rethinking use of medicines for chronic pain – The BMJ
News Release: Antidepressants use for chronic pain on the rise, but are they effective? – University of Sidney
Commentary from the author on Twitter (thread – click for more)
Out today in @bmj_latest
We reviewed the evidence on the efficacy of antidepressants for pain in adults
We showed that antidepressants are effective for some pain conditions, but for most they are either ineffective or evidence is inconclusivehttps://t.co/E2XVQ9oGUQ
? pic.twitter.com/kBo7eAyeCP— Giovanni Ferreira (@giovanni_ef) February 1, 2023
Patients labeled as nonallergic after initial tests for penicillin allergy may develop resensitization afterwards
2 Feb, 2023 | 15:03h | UTCResensitization in suspected penicillin allergy – Allergy
Video summary: Resensitisation in suspected penicillin allergy
Commentary: Patients should be retested for penicillin resensitization before being deemed nonallergic – Healio (free registration required)
Related:
M-A: Most patients with allergy to Penicillin can be given Cefazolin
Podcast: A Clinical Pharmacologist’s Perspective on Penicillin Allergy
Study: Development and Validation of a Penicillin Allergy Clinical Decision Rule
NICE: Double Check Patients with ‘Penicillin Allergy’ to Avoid Increased MRSA Risk
Commentary on Twitter
Doña et al. Resensitization in suspected #penicillinallergy
Read ? https://t.co/irMhv07kN5
Video abstract of this article ? https://t.co/JIzDlQROYN
Read all recent papers published in #Allergy on #drugallergies ? https://t.co/jUxpXPlxKB@mariajtorresj #Allergy_journal pic.twitter.com/eIB1TdDqPI
— Allergy EAACI (@AllergyEaaci) November 15, 2022
Preliminary study suggests chemotherapy delivery in the afternoon may improve outcomes in patients with DLBC lymphoma
1 Feb, 2023 | 13:27h | UTCCommentaries:
Chemotherapy schedule affects treatment outcomes in female DLBCL patients – News Medical
Review | Safety and effectiveness of NMDA receptor antagonists for depression
1 Feb, 2023 | 13:05h | UTC
M-A | Vancomycin area under the curve vs. trough only guided dosing and the risk of acute kidney injury
31 Jan, 2023 | 13:32h | UTC
A new study provides insights into the emotional ‘blunting’ caused by common antidepressants
30 Jan, 2023 | 01:05h | UTCNews Release: Scientists explain emotional ‘blunting’ caused by common antidepressants – University of Cambridge
Commentary from the authors: Emotional ‘blunting’ and antidepressants – new research suggests why this is happening – The Conversation
Commentary on Twitter
One of our top rated articles on @altmetric this week was published in @npp_journal. Read 'Chronic escitalopram in healthy volunteers has specific effects on reinforcement sensitivity: a double-blind, placebo-controlled semi-randomised study' here: https://t.co/4W8XGoyYMn pic.twitter.com/C1XKcglGtW
— Springer Nature (@SpringerNature) January 27, 2023
FDA panel eyes shift to annual COVID shots
30 Jan, 2023 | 01:03h | UTCFDA panel eyes shift to annual COVID shots – CIDRAP
See also:
FDA advisers recommend updating Covid vaccines – STAT
U.S. Proposes to Make COVID Shot Annual, Much Like Flu Shot – HealthDay
Case Series | Higher Troponin was associated with persistent cardiac MRI lesions in children with myocarditis after mRNA-based COVID-19 vaccination
30 Jan, 2023 | 01:01h | UTC
Evaluation of systemic medications associated with surgically treated cataract among US adults
30 Jan, 2023 | 00:38h | UTCCommentary: Some systemic medications may be associated with increased cataract risk – 2 Minute Medicine
Overuse of medications in low- and middle-income countries: a scoping review
27 Jan, 2023 | 12:31h | UTC
Perspective | Were bivalent boosters worth it? The biggest questions about the newest Covid-19 vaccines are still unanswered
27 Jan, 2023 | 12:19h | UTC
SR | Barriers and facilitators to deprescribing of cardiovascular medications
27 Jan, 2023 | 12:09h | UTCRelated:
Review | The blood–brain barrier and optimization of antibiotics for the treatment of CNS infections in adults
27 Jan, 2023 | 11:55h | UTC
Essential medicines for mental disorders: comparison of 121 national lists with WHO recommendations
26 Jan, 2023 | 12:55h | UTC